Compare SSB & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSB | KYMR |
|---|---|---|
| Founded | 1933 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 9.0B |
| IPO Year | 2008 | 2020 |
| Metric | SSB | KYMR |
|---|---|---|
| Price | $102.72 | $121.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 24 |
| Target Price | $119.64 | ★ $145.22 |
| AVG Volume (30 Days) | 718.2K | ★ 912.7K |
| Earning Date | 10-21-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | ★ 12.91 | N/A |
| EPS | ★ 6.93 | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $1.59 | $153.48 |
| Revenue Next Year | $7.06 | N/A |
| P/E Ratio | $14.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $85.51 | $63.69 |
| 52 Week High | $112.20 | $142.92 |
| Indicator | SSB | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 47.18 |
| Support Level | $100.33 | $104.96 |
| Resistance Level | $104.34 | $128.95 |
| Average True Range (ATR) | 2.10 | 7.47 |
| MACD | -0.38 | -1.35 |
| Stochastic Oscillator | 3.01 | 14.51 |
SouthState Bank Corp is a United States-based bank holding company. It provides a wide range of services and products to its customers through a wholly-owned bank subsidiary. The Bank provides retail and commercial banking services, mortgage lending services, trust and investment services, and consumer finance loans through financial centers in Alabama, Florida, Georgia, North Carolina, South Carolina, and Virginia. These services include demand, time, and savings deposits, lending and credit card servicing, ATM processing, and wealth management and trust services.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.